Paltusotine hydrochloride is a orally active, non-peptide selective somatostatin type 2 (SST2) receptor agonist with the potential to maintain GH and IGF-1 levels following treatment with long-acting somatostatin receptor ligands; it is used in the research of acromegaly and neuroendocrine tumors.